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Background
In mice, cryo plus checkpoint blockade facilitates tumor
antigen release, T-cell priming, and improved survival
[1]. Here, we assess immune response in ESBC patients
using biomarkers that have been attributed to clinical
benefit following checkpoint blockade [2-5].
Methods
Women with ESBC were treated 7-10 days preceding
mastectomy with either cryo (n=6), single-dose ipi at
10mg/kg (n=6), or cryo+ipi (n=6) [6]. From serial blood
(baseline & 1-month post-mastectomy) and tumor
(biopsy & mastectomy), fold-changes following cryo+ipi
versus monotherapy were compared (Wilcoxon rank-
sum) across the following measures: Ki67+ or ICOShi
T-cells [2] and intratumoral T-effector/T-regulatory [3]
cells by flow cytometry, plasma Th1/Th2 cytokines [4]
(Meso Scale Discovery), and intratumoral T-cell expan-
sion by immunohistochemistry [5] and T-cell receptor
(TCR) deep sequencing (ImmunoSEQ) [5].
Results
Cryo+ipi generated greater increases in peripheral Ki67
+CD4+ (p=0.05), Ki67+CD8+ (p=0.05), ICOShiCD4+
(p=0.005), and ICOShiCD8+ (p=0.005) cells. The
intratumoral T-effector/regulatory ratio was higher fol-
lowing cryo+ipi, but only when Ki67-gated (p=.01). Cryo
+ipi generated greater increases in IL-2 (p=.01), IFNÎ³
(p=.06), and IL-5 (p=.09). Despite negligible intratu-
moral changes by immunohistochemistry, cryo+ipi gen-
erated more high-magnitude (~1000 amplicon) clonal
expansions by TCR sequencing (medians: 52 v. 3
clones).
Conclusions
Cryo+ipi is associated with potentially favorable immuno-
logic effects. Ki67-gating and TCR sequencing may iden-
tify intratumoral changes otherwise undetectable by flow
or IHC.
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